What is the China Select Committee?

The China Select Committee is a special US House committee tasked with overseeing Chinese activities affecting US interests.

Have AbbVie or Merck commented?

Neither company has issued an official statement yet, but both are expected to cooperate.

What is the potential impact on ABBV and MRK shares?

Not yet determined, but any penalties could affect their China operations, a key pharmaceutical market.

US House Committee Probes AbbVie, Merck Over China Clinical Trials

AbbVie (ABBV) and Merck (MRK) are under investigation by the US House China Select Committee regarding clinical trials performed in China. The scope of the probe remains undisclosed.

June 30, 2026

2 min read

Source: MT Newswires

Pharmaceutical giants AbbVie (ABBV) and Merck (MRK) are facing an investigation by the US House of Representatives' China Select Committee over clinical trials conducted in China, according to sources.

Details of the Probe

The committee, tasked with overseeing Chinese activities affecting US interests, is examining whether the companies complied with US regulations and ethical standards during clinical trials in China. The specific scope and evidence have not been disclosed.

Company Response

Neither AbbVie nor Merck has issued an official statement. Both are expected to cooperate with the investigation.

Precedents and Context

The probe comes amid rising US-China tensions, with several American pharmaceutical and tech companies facing increased scrutiny over their China operations. Previously, Pfizer and Johnson & Johnson faced similar inquiries.

Potential Financial Impact

No financial penalties have been specified yet. However, adverse findings could impact the companies' operations in China, one of the world's largest pharmaceutical markets.

Frequently Asked Questions

The committee is examining whether the companies complied with US regulations and ethical standards during clinical trials in China.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.